




Mycoplasma hyopneumoniae (*M.hyo*) is a primary pathogen of the porcine respiratory system and is the causative agent of Enzootic pneumonia (EP). *M.hyo* also has a large role in the development of the Porcine Respiratory Disease Complex (PRDC). *M.hyo* is widespread throughout the pig population and is endemic on most farms worldwide.

EP has a large economic impact on the pig industry, primarily due to the cost of treatment, reduced performance and increased mortality due to secondary infections [1].



Vaccination is commonly used to control the disease and has been shown to improve the daily weight gain by 2-8% and the feed conversion ratio by 2-5%, therefore reducing losses due to EP [2].



Economic analysis has been completed for units in the UK which have implemented a Hyogen® vaccination protocol and the benefit of vaccinating with Hyogen® has been shown to be **£1 per pig**. This is based on the reduction in frequency and severity of EP-like lesions observed in the slaughterhouse and the consequential improvement of daily live weight gain and feed conversion ratio, combined with reduced mortality.

Hyogen® use has been shown to be effective at reducing both the percentage of pigs with EP-like lesions but also the severity of these lesions, as demonstrated by the Madec index which is calculated using a modified Madec score. The Ceva Lung Program is a tool for analysis of the lungs in the slaughterhouse and has been used in the UK to

demonstrate these reductions. Farm A and B are examples of this in the UK and have demonstrated an average reduction of 60% in the percentage of bronchopneumonic lungs and 65% in the Madec index when vaccinating with Hyogen® compared to competitor vaccines (Figure 1 and 2).



[1] Holst, S., Yeske, P. and Pieters, M. 2015. Elimination of *Mycoplasma hyopneumoniae* from breed-to-wean farms: A review of current protocols with emphasis on herd closure and medication. *J Swine Health Prod*, 23(6), pp. 321–330.





[2] Segales, J., Meyns, T., Sibila, M., Pieters, M. and Haesebrouck, F. 2008. Control of *Mycoplasma hyopneumoniae* infections in pigs. *Veterinary Microbiology*, 126(4), pp. 297–309.

Hyogen®

WITH **Imuvant™**



Leading Mycoplasma Protection

-  Contains Imuvant™, a unique Ceva adjuvant
-  Single shot vaccination from 21 days of age
-  Long lasting protection for up to 26 weeks
-  Support from the Ceva Lung Program and Respinomics™



Active ingredient: Hyogen contains Inactivated Mycoplasma hyopneumoniae 2940 strain. Further information available on the SPC. Use medicines responsibly (www.noah.co.uk/responsible)

Legal category: UK **POM-V** IE **POM**

Advice should be sought from your prescribing veterinary surgeon. For further information contact:

Ceva Animal Health Ltd

Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks HP7 9FB

Tel: 01494 781510 www.ceva.co.uk

